Madhumita Shrotri1, Maria Krutikov2, Tom Palmer3, Rebecca Giddings2, Borscha Azmi2, Sathyavani Subbarao4, Christopher Fuller2, Aidan Irwin-Singer5, Daniel Davies6, Gokhan Tut7, Jamie Lopez Bernal4, Paul Moss7, Andrew Hayward8, Andrew Copas3, Laura Shallcross9. 1. UCL Institute of Health Informatics, UCL, London, UK; Public Health England, London, UK. 2. UCL Institute of Health Informatics, UCL, London, UK. 3. UCL Institute for Global Health, UCL, London, UK. 4. Public Health England, London, UK. 5. Department of Health and Social Care, London, UK. 6. Palantir Technologies UK, London, UK. 7. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. 8. UCL Institute of Epidemiology & Healthcare, UCL, London, UK; Health Data Research UK, London, UK. 9. UCL Institute of Health Informatics, UCL, London, UK. Electronic address: l.shallcross@ucl.ac.uk.
Abstract
BACKGROUND: The effectiveness of SARS-CoV-2 vaccines in older adults living in long-term care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and the Pfizer-BioNTech mRNA-based vaccine (BNT162b2) in residents of long-term care facilities in terms of PCR-confirmed SARS-CoV-2 infection over time since vaccination. METHODS: The VIVALDI study is a prospective cohort study that commenced recruitment on June 11, 2020, to investigate SARS-CoV-2 transmission, infection outcomes, and immunity in residents and staff in long-term care facilities in England that provide residential or nursing care for adults aged 65 years and older. In this cohort study, we included long-term care facility residents undergoing routine asymptomatic SARS-CoV-2 testing between Dec 8, 2020 (the date the vaccine was first deployed in a long-term care facility), and March 15, 2021, using national testing data linked within the COVID-19 Datastore. Using Cox proportional hazards regression, we estimated the relative hazard of PCR-positive infection at 0-6 days, 7-13 days, 14-20 days, 21-27 days, 28-34 days, 35-48 days, and 49 days and beyond after vaccination, comparing unvaccinated and vaccinated person-time from the same cohort of residents, adjusting for age, sex, previous infection, local SARS-CoV-2 incidence, long-term care facility bed capacity, and clustering by long-term care facility. We also compared mean PCR cycle threshold (Ct) values for positive swabs obtained before and after vaccination. The study is registered with ISRCTN, number 14447421. FINDINGS: 10 412 care home residents aged 65 years and older from 310 LTCFs were included in this analysis. The median participant age was 86 years (IQR 80-91), 7247 (69·6%) of 10 412 residents were female, and 1155 residents (11·1%) had evidence of previous SARS-CoV-2 infection. 9160 (88·0%) residents received at least one vaccine dose, of whom 6138 (67·0%) received ChAdOx1 and 3022 (33·0%) received BNT162b2. Between Dec 8, 2020, and March 15, 2021, there were 36 352 PCR results in 670 628 person-days, and 1335 PCR-positive infections (713 in unvaccinated residents and 612 in vaccinated residents) were included. Adjusted hazard ratios (HRs) for PCR-positive infection relative to unvaccinated residents declined from 28 days after the first vaccine dose to 0·44 (95% CI 0·24-0·81) at 28-34 days and 0·38 (0·19-0·77) at 35-48 days. Similar effect sizes were seen for ChAdOx1 (adjusted HR 0·32, 95% CI 0·15-0·66) and BNT162b2 (0·35, 0·17-0·71) vaccines at 35-48 days. Mean PCR Ct values were higher for infections that occurred at least 28 days after vaccination than for those occurring before vaccination (31·3 [SD 8·7] in 107 PCR-positive tests vs 26·6 [6·6] in 552 PCR-positive tests; p<0·0001). INTERPRETATION: Single-dose vaccination with BNT162b2 and ChAdOx1 vaccines provides substantial protection against infection in older adults from 4-7 weeks after vaccination and might reduce SARS-CoV-2 transmission. However, the risk of infection is not eliminated, highlighting the ongoing need for non-pharmaceutical interventions to prevent transmission in long-term care facilities. FUNDING: UK Government Department of Health and Social Care.
BACKGROUND: The effectiveness of SARS-CoV-2 vaccines in older adults living in long-term care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and the Pfizer-BioNTech mRNA-based vaccine (BNT162b2) in residents of long-term care facilities in terms of PCR-confirmed SARS-CoV-2 infection over time since vaccination. METHODS: The VIVALDI study is a prospective cohort study that commenced recruitment on June 11, 2020, to investigate SARS-CoV-2 transmission, infection outcomes, and immunity in residents and staff in long-term care facilities in England that provide residential or nursing care for adults aged 65 years and older. In this cohort study, we included long-term care facility residents undergoing routine asymptomatic SARS-CoV-2 testing between Dec 8, 2020 (the date the vaccine was first deployed in a long-term care facility), and March 15, 2021, using national testing data linked within the COVID-19 Datastore. Using Cox proportional hazards regression, we estimated the relative hazard of PCR-positive infection at 0-6 days, 7-13 days, 14-20 days, 21-27 days, 28-34 days, 35-48 days, and 49 days and beyond after vaccination, comparing unvaccinated and vaccinated person-time from the same cohort of residents, adjusting for age, sex, previous infection, local SARS-CoV-2 incidence, long-term care facility bed capacity, and clustering by long-term care facility. We also compared mean PCR cycle threshold (Ct) values for positive swabs obtained before and after vaccination. The study is registered with ISRCTN, number 14447421. FINDINGS: 10 412 care home residents aged 65 years and older from 310 LTCFs were included in this analysis. The median participant age was 86 years (IQR 80-91), 7247 (69·6%) of 10 412 residents were female, and 1155 residents (11·1%) had evidence of previous SARS-CoV-2 infection. 9160 (88·0%) residents received at least one vaccine dose, of whom 6138 (67·0%) received ChAdOx1 and 3022 (33·0%) received BNT162b2. Between Dec 8, 2020, and March 15, 2021, there were 36 352 PCR results in 670 628 person-days, and 1335 PCR-positive infections (713 in unvaccinated residents and 612 in vaccinated residents) were included. Adjusted hazard ratios (HRs) for PCR-positive infection relative to unvaccinated residents declined from 28 days after the first vaccine dose to 0·44 (95% CI 0·24-0·81) at 28-34 days and 0·38 (0·19-0·77) at 35-48 days. Similar effect sizes were seen for ChAdOx1 (adjusted HR 0·32, 95% CI 0·15-0·66) and BNT162b2 (0·35, 0·17-0·71) vaccines at 35-48 days. Mean PCR Ct values were higher for infections that occurred at least 28 days after vaccination than for those occurring before vaccination (31·3 [SD 8·7] in 107 PCR-positive tests vs 26·6 [6·6] in 552 PCR-positive tests; p<0·0001). INTERPRETATION: Single-dose vaccination with BNT162b2 and ChAdOx1 vaccines provides substantial protection against infection in older adults from 4-7 weeks after vaccination and might reduce SARS-CoV-2 transmission. However, the risk of infection is not eliminated, highlighting the ongoing need for non-pharmaceutical interventions to prevent transmission in long-term care facilities. FUNDING: UK Government Department of Health and Social Care.
Authors: Giulia Lamacchia; Alessio Mazzoni; Michele Spinicci; Anna Vanni; Lorenzo Salvati; Benedetta Peruzzi; Sara Bencini; Manuela Capone; Alberto Carnasciali; Parham Farahvachi; Arianna Rocca; Seble Tekle Kiros; Lucia Graziani; Lorenzo Zammarchi; Jessica Mencarini; Maria Grazia Colao; Roberto Caporale; Francesco Liotta; Lorenzo Cosmi; Gian Maria Rossolini; Alessandro Bartoloni; Laura Maggi; Francesco Annunziato Journal: J Clin Immunol Date: 2022-07-09 Impact factor: 8.317
Authors: Madhumita Shrotri; Maria Krutikov; Hadjer Nacer-Laidi; Borscha Azmi; Tom Palmer; Rebecca Giddings; Christopher Fuller; Aidan Irwin-Singer; Verity Baynton; Gokhan Tut; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross Journal: Lancet Healthy Longev Date: 2022-07-04
Authors: Kate M Bubar; Casey E Middleton; Kristen K Bjorkman; Roy Parker; Daniel B Larremore Journal: Nat Commun Date: 2022-05-19 Impact factor: 17.694
Authors: William J Hulme; Elizabeth J Williamson; Amelia C A Green; Krishnan Bhaskaran; Helen I McDonald; Christopher T Rentsch; Anna Schultze; John Tazare; Helen J Curtis; Alex J Walker; Laurie A Tomlinson; Tom Palmer; Elsie M F Horne; Brian MacKenna; Caroline E Morton; Amir Mehrkar; Jessica Morley; Louis Fisher; Sebastian C J Bacon; David Evans; Peter Inglesby; George Hickman; Simon Davy; Tom Ward; Richard Croker; Rosalind M Eggo; Angel Y S Wong; Rohini Mathur; Kevin Wing; Harriet Forbes; Daniel J Grint; Ian J Douglas; Stephen J W Evans; Liam Smeeth; Chris Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Jonathan A C Sterne; Miguel A Hernán; Ben Goldacre Journal: BMJ Date: 2022-07-20
Authors: Thomas Harder; Judith Koch; Sabine Vygen-Bonnet; Wiebe Külper-Schiek; Antonia Pilic; Sarah Reda; Stefan Scholz; Ole Wichmann Journal: Euro Surveill Date: 2021-07
Authors: Koen B Pouwels; David W Eyre; A Sarah Walker; Jia Wei; Nicole Stoesser; Philippa C Matthews; Daniel Ayoubkhani; Ruth Studley; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim E A Peto Journal: Nat Microbiol Date: 2021-07-21 Impact factor: 17.745